High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients
BackgroundCellular immunodeficiency and comorbidities are common in COVID-19 patients.AimThe purpose of this study was to investigate comorbidities impacting on the cellular immunity in COVID-19 patients.MethodsThe research objects included 55 healthy controls and 718 COVID-19 patients who divided i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.899930/full |
| _version_ | 1818532893291446272 |
|---|---|
| author | Dafeng Liu Dafeng Liu Xiaoyan Yuan Xiaoyan Yuan Fengjiao Gao Fengjiao Gao Bennan Zhao Bennan Zhao Ling Ding Ling Ding Mingchang Huan Mingchang Huan Chao Liu Chao Liu Liangshuang Jiang Liangshuang Jiang |
| author_facet | Dafeng Liu Dafeng Liu Xiaoyan Yuan Xiaoyan Yuan Fengjiao Gao Fengjiao Gao Bennan Zhao Bennan Zhao Ling Ding Ling Ding Mingchang Huan Mingchang Huan Chao Liu Chao Liu Liangshuang Jiang Liangshuang Jiang |
| author_sort | Dafeng Liu |
| collection | DOAJ |
| description | BackgroundCellular immunodeficiency and comorbidities are common in COVID-19 patients.AimThe purpose of this study was to investigate comorbidities impacting on the cellular immunity in COVID-19 patients.MethodsThe research objects included 55 healthy controls and 718 COVID-19 patients who divided into the control group and the COVID-19 group, respectively. Those in the COVID-19 group were divided into subgroups on the basis of the number and types of comorbidities present. Lymphocyte itself and its subsets were compared between the control group and the COVID-19 group, the groups with comorbidities based on the different number and types of comorbidities, and the relationship between the lymphocyte counts and subsets with the number and types of comorbidities was investigated.ResultsCompared with the control group, the lymphocyte counts and T cell subsets were significantly increased in the groups with comorbidities, but both B and NK cell subsets were significantly decreased in the no comorbidity group and in most of the groups with comorbidities (all P<0.05). In the three comorbidities group, the lymphocyte counts and T cell subsets were all significantly decreased, but the CD56+ percentage was obviously increased (all P<0.05). The number of comorbidities was negatively correlated with the lymphocyte counts and the T and NK cell subsets. A negative correlation also existed between cancer and both the lymphocyte counts and the T cell subsets, between chronic hepatitis B and the lymphocyte counts, and between chronic kidney disease and the CD3+ counts. A positive correlation existed between nonalcoholic fatty liver disease (NAFLD) disease and both lymphocyte and CD3+ counts. The risk factors were number of comorbidities for the lymphocyte count, CD3+CD4+ and CD3+CD8+ percentages, NAFLD for the lymphocyte and CD3+ counts, cardiovascular diseases for CD3+CD4+ and CD3+CD8+ percentages, diabetes mellitus for the CD3+CD8+ percentage, and cancer for the CD3+ percentage, respectively.ConclusionsHigh numbers of comorbidities and specific comorbidities could impact the immune response of COVID-19 patients. This study provides a reference for clinicians in the identification of suitable and timely immunotherapy for COVID-19 patients.Clinical Trial Registryhttps://www.chictr.org.cn/enindex.aspx, identifier ChiCTR2000034563. |
| first_indexed | 2024-12-11T17:51:29Z |
| format | Article |
| id | doaj.art-f4e68e9b27e34c15a2680155668e4346 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T17:51:29Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f4e68e9b27e34c15a2680155668e43462022-12-22T00:56:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.899930899930High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 PatientsDafeng Liu0Dafeng Liu1Xiaoyan Yuan2Xiaoyan Yuan3Fengjiao Gao4Fengjiao Gao5Bennan Zhao6Bennan Zhao7Ling Ding8Ling Ding9Mingchang Huan10Mingchang Huan11Chao Liu12Chao Liu13Liangshuang Jiang14Liangshuang Jiang15Department of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaPublic Health and Clinical Centre of Chengdu Substation, Chengdu New Emergent Infectious Disease Prevention and Control Workstation, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaPublic Health and Clinical Centre of Chengdu Substation, Chengdu New Emergent Infectious Disease Prevention and Control Workstation, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaPublic Health and Clinical Centre of Chengdu Substation, Chengdu New Emergent Infectious Disease Prevention and Control Workstation, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaPublic Health and Clinical Centre of Chengdu Substation, Chengdu New Emergent Infectious Disease Prevention and Control Workstation, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaDepartment of Pediatrics, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaDepartment of Surgery, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaDepartment of Surgery, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaDepartment of Internal Medicine, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaVice President’s Office, Public Health and Clinical Centre of Chengdu, Chengdu, ChinaBackgroundCellular immunodeficiency and comorbidities are common in COVID-19 patients.AimThe purpose of this study was to investigate comorbidities impacting on the cellular immunity in COVID-19 patients.MethodsThe research objects included 55 healthy controls and 718 COVID-19 patients who divided into the control group and the COVID-19 group, respectively. Those in the COVID-19 group were divided into subgroups on the basis of the number and types of comorbidities present. Lymphocyte itself and its subsets were compared between the control group and the COVID-19 group, the groups with comorbidities based on the different number and types of comorbidities, and the relationship between the lymphocyte counts and subsets with the number and types of comorbidities was investigated.ResultsCompared with the control group, the lymphocyte counts and T cell subsets were significantly increased in the groups with comorbidities, but both B and NK cell subsets were significantly decreased in the no comorbidity group and in most of the groups with comorbidities (all P<0.05). In the three comorbidities group, the lymphocyte counts and T cell subsets were all significantly decreased, but the CD56+ percentage was obviously increased (all P<0.05). The number of comorbidities was negatively correlated with the lymphocyte counts and the T and NK cell subsets. A negative correlation also existed between cancer and both the lymphocyte counts and the T cell subsets, between chronic hepatitis B and the lymphocyte counts, and between chronic kidney disease and the CD3+ counts. A positive correlation existed between nonalcoholic fatty liver disease (NAFLD) disease and both lymphocyte and CD3+ counts. The risk factors were number of comorbidities for the lymphocyte count, CD3+CD4+ and CD3+CD8+ percentages, NAFLD for the lymphocyte and CD3+ counts, cardiovascular diseases for CD3+CD4+ and CD3+CD8+ percentages, diabetes mellitus for the CD3+CD8+ percentage, and cancer for the CD3+ percentage, respectively.ConclusionsHigh numbers of comorbidities and specific comorbidities could impact the immune response of COVID-19 patients. This study provides a reference for clinicians in the identification of suitable and timely immunotherapy for COVID-19 patients.Clinical Trial Registryhttps://www.chictr.org.cn/enindex.aspx, identifier ChiCTR2000034563.https://www.frontiersin.org/articles/10.3389/fimmu.2022.899930/fulllymphocyte subsetscoronavirus disease 2019 (COVID-19)comorbiditiesimpactimmune response |
| spellingShingle | Dafeng Liu Dafeng Liu Xiaoyan Yuan Xiaoyan Yuan Fengjiao Gao Fengjiao Gao Bennan Zhao Bennan Zhao Ling Ding Ling Ding Mingchang Huan Mingchang Huan Chao Liu Chao Liu Liangshuang Jiang Liangshuang Jiang High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients Frontiers in Immunology lymphocyte subsets coronavirus disease 2019 (COVID-19) comorbidities impact immune response |
| title | High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients |
| title_full | High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients |
| title_fullStr | High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients |
| title_full_unstemmed | High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients |
| title_short | High Number and Specific Comorbidities Could Impact the Immune Response in COVID-19 Patients |
| title_sort | high number and specific comorbidities could impact the immune response in covid 19 patients |
| topic | lymphocyte subsets coronavirus disease 2019 (COVID-19) comorbidities impact immune response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.899930/full |
| work_keys_str_mv | AT dafengliu highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT dafengliu highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT xiaoyanyuan highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT xiaoyanyuan highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT fengjiaogao highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT fengjiaogao highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT bennanzhao highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT bennanzhao highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT lingding highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT lingding highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT mingchanghuan highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT mingchanghuan highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT chaoliu highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT chaoliu highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT liangshuangjiang highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients AT liangshuangjiang highnumberandspecificcomorbiditiescouldimpacttheimmuneresponseincovid19patients |